Impacts of cost containment strategies on pharmaceutical expenditures of the National Health Insurance in Taiwan, 1996-2003.
about
Pharmaceutical policies: effects of cap and co-payment on rational use of medicinesPharmaceutical policies: effects of reference pricing, other pricing, and purchasing policiesPayment methods for ambulatory care facilitiesPharmaceutical policies: effects of cap and co-payment on rational drug useChanges in drug utilization during a gap in insurance coverage: an examination of the medicare Part D coverage gapPayment methods for outpatient care facilities.The influences of Taiwan's generic grouping price policy on drug prices and expenditures: evidence from analysing the consumption of the three most-used classes of cardiovascular drugsPrice regulation, new entry, and information shock on pharmaceutical market in Taiwan: a nationwide data-based study from 2001 to 2004Impact of drug price adjustments on utilization of and expenditures on angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in Taiwan.Efficacy, safety and tolerability of ongoing statin plus ezetimibe versus doubling the ongoing statin dose in hypercholesterolemic Taiwanese patients: an open-label, randomized clinical trialThe evolution of Taiwan's National Health Insurance drug reimbursement schemeSelecting the Acceptance Criteria of Medicines in the Reimbursement List of Public Health Insurance of Iran, Using the "Borda" Method: a Pilot StudyThe impact of the global budget system on dynamics of dental manpower and utilization of dental servicesBrand name or generic? What are the health professionals prescribed for treating diabetes? A longitudinal analysis of the National Health Insurance reimbursement database.Policy options for pharmaceutical pricing and purchasing: issues for low- and middle-income countries.Reimbursement changes and drug switching: are severe patients more affected?The impact of repeated cost containment policies on pharmaceutical expenditure: experience in Spain.Drugs cheaper than threepenny: the market of extremely low-priced drugs within the National Health Insurance in Taiwan
P2860
Q24188009-3031C3EA-C4B7-4F37-879B-0C3A0BA29BDBQ24193097-E6D8D927-892B-49EC-8A3C-A4230D9CA454Q24194346-78911F88-97AE-494C-9438-B7F8598B4300Q24242490-468D24ED-949F-4288-B9A0-EB9ACED30829Q28476575-0BBDA3DB-EC5B-4B88-96DA-9ACE09B96CD3Q30399359-C7202CC9-8209-41A8-8E76-98DE0244EA23Q33327778-011137FC-1369-4427-BB63-01CC3D69E631Q33639030-152DBD9C-AC32-497C-90FF-0CAD8FE6C31BQ34240897-325B13A9-24DA-43A2-A6C6-EF5021C43DD4Q34279028-EFD3DEB8-AB05-43CD-A3A4-0FCAE1E22331Q35099630-77AB75DF-B67E-4AB4-AB31-EF7976F3E5EDQ36358445-DA5E97F4-96A9-437D-9E70-7AFCD89C4C2DQ36737342-FA010EC3-DB93-472B-915F-E37FC2400F42Q38102656-08962EA3-1950-498F-B3AD-F7FA4869CC89Q38178581-06202207-ABEB-4D8D-9236-FA149F3E0709Q47877693-96B23826-1554-4B14-B73E-30C53F72CB53Q51151532-68D76262-6A5F-4D10-A92F-A9385D832D7CQ59075042-55336D09-B0F0-4EB4-9C4B-07E3498ADFD7
P2860
Impacts of cost containment strategies on pharmaceutical expenditures of the National Health Insurance in Taiwan, 1996-2003.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Impacts of cost containment st ...... nsurance in Taiwan, 1996-2003.
@en
type
label
Impacts of cost containment st ...... nsurance in Taiwan, 1996-2003.
@en
prefLabel
Impacts of cost containment st ...... nsurance in Taiwan, 1996-2003.
@en
P2093
P1433
P1476
Impacts of cost containment st ...... nsurance in Taiwan, 1996-2003.
@en
P2093
Chien-Hsiang Liu
Ming-Chin Yang
Sun-Bing Chen
Yu-Tung Huang
Yue-Chune Lee
P304
P356
10.2165/00019053-200624090-00006
P577
2006-01-01T00:00:00Z
P6179
1021413943